Sandoz Seeks Help From Doctors For US Symjepi Push
Sandoz is encouraging US doctors to write prescriptions for epinephrine that include its Symjepi pre-filled syringes, and not just for auto-injector devices, as it targets the retail sector.
You may also be interested in...
Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.
Sandoz has set a US launch price for its Symjepi epinephrine anaphylaxis treatment that is significantly below that of Mylan’s EpiPen and Teva’s generic.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.